CRIS.OQ - Curis Inc
Curis Inc
Laidlaw & Company

Laidlaw: CRIS: 4Q25: Emavusertib in CLL and PCNSL development are the largest commercial opportunities and fastest to market

公司
CRIS.OQ
日期
2026-03-20
分析师
Mr. Yale I. Jen, PHD
页数
7
需要登录
请登录后购买研报或生成音频内容。